Table 2. FDA-approved drugs for mRCC.

Cytokine

Recombinant interleukin-2

Inhibitors of VEGF signaling

Sunitinib

Pazopanib

Sorafenib

Axitinib

Bevacizumab (with interferon-α)

mTOR inhibitors

Temsirolims

Everolimus

Abbreviations: FDA, U.S. Food and Drug Administration; mRCC, metastatic renal cell carcinoma; mTOR, mammalian target of rapamycin.